52160 Federal Register / Vol. 86, No. 179 / Monday, September 20, 2021 / Notices 

and relabeling them to represent 

different experiments in three (3) figure 

panels in one (1) paper, including: 

—Figure 3 in J Biol Chem. 2014, 

representing chromatin-bound gH2AX levels in WT MEF (Figure 3A), 

Ogg1¥/¥ MEF (Figure 3C), and Ogg1+

(rescue) MEF (Figure 3D) cells 

transfected with a control or 

expression vector and in the absence 

or presence of irradiation 

Dr. Wang entered into a Voluntary 

Exclusion Agreement (Agreement) and 

voluntarily agreed to the following: 

(1) Respondent agreed to exclude 

herself voluntarily for a period of four 

(4) years beginning on August 4, 2021, 

from any contracting or subcontracting 

with any agency of the United States 

Government and from eligibility for or 

involvement in nonprocurement 

programs of the United States 

Government referred to as ‘‘covered 

transactions’’ pursuant to HHS’ 

Implementation (2 CFR part 376) of 

OMB Guidelines to Agencies on 

Governmentwide Debarment and 

Suspension, 2 CFR part 180 (collectively 

the ‘‘Debarment Regulations’’). 

(2) Respondent agreed to exclude 

herself voluntarily from serving in any 

advisory capacity to PHS including, but 

not limited to, service on any PHS 

advisory committee, board, and/or peer 

review committee, or as a consultant for 

a period of four (4) years, beginning on 

August 4, 2021. 

(3) As a condition of the Agreement, 

Respondent will request that the 

following papers be corrected or 

retracted in accordance with 42 CFR 

93.407(a)(1) and § 93.411(b): 

• Cell Death Dis. 2014 Jan;5(1):e1024 

• Cancer Res. 2012 Sep 15;72(18):4707– 

13 

• Cancer Res. 2012 Mar 1;72(5):1221–8 

• DNA Repair (Amst). 2010 Nov 

10;9(11):1170–5 

Respondent will copy ORI and the 

Research Integrity Officer at EU on the 

correspondence. 

Dated: September 15, 2021. 

Wanda K. Jones, 

Acting Director, Office of Research Integrity, 

Office of the Assistant Secretary for Health. 

[FR Doc. 2021–20268 Filed 9–17–21; 8:45 am] 

BILLING CODE 4150–31–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

[Document Identifier: OS–0990–xxxx] 

Agency Father Generic Information 

Collection Request. 60-Day Public 

Comment Request 

AGENCY: Office of the Secretary, Health 

and Human Services (HHS). 

ACTION: 60-Day notice of public 

information collections. 

SUMMARY: In compliance with the 

requirement of the Paperwork 

Reduction Act of 1995, the Office of the 

Secretary (OS), Department of Health 

and Human Services, is publishing the 

following summary of a proposed 

collection for public comment. 

DATES: Comments on the ICR must be 

received on or before November 19, 

2021. 

ADDRESSES: Submit your comments to 

Sherrette.Funn@hhs.gov or by calling 

(202) 795–7714. 

FOR FURTHER INFORMATION CONTACT: 

When submitting comments or 

requesting information, please include 

the document identifier 0990-New-60D, 

and project title for reference, to 

Sherrette Funn, the Reports Clearance 

Officer, Sherrette.funn@hhs.gov, or call 

202–795–7714. 

SUPPLEMENTARY INFORMATION: Interested 

persons are invited to send comments 

regarding this burden estimate or any 

other aspect of this collection of 

information, including any of the 

following subjects: (1) The necessity and 

utility of the proposed information 

collection for the proper performance of 

the agency’s functions; (2) the accuracy 

of the estimated burden; (3) ways to 

enhance the quality, utility, and clarity 

of the information to be collected; and 

(4) the use of automated collection 

techniques or other forms of information 

technology to minimize the information 

collection burden. 

Title of the Collection: Evaluation of 

the National Hypertension Control 

Initiative (NHCI). 

Type of Collection: NEW Generic. 

OMB No. 0990—OS/Office of Minority 

Health (OMH) 

Abstract: As part of the federal 

response to COVID–19, the U.S. 

Department of Health and Human 

Services (HHS) has funded a new 

initiative involving two cooperative 

agreements with the American Heart 

Association (AHA) to improve COVID– 

19-related health outcomes by 

addressing hypertension (high blood 

pressure) among racial and ethnic 

minority populations. 

The $32 million project from the HHS 

Office of Minority Health (OMH) and 

the Health Resources and Services 

Administration (HRSA) Bureau of 

Primary Health Care will support the 

implementation of the National 

Hypertension Control Initiative (NHCI), 

a national initiative to improve blood 

pressure control among the most at-risk 

populations, including racial and ethnic 

minorities. 

The NHCI will support 350 

participating HRSA-funded health 

centers by providing patient and 

provider education and training for 

effective hypertension control as well as 

integration of remote blood pressure 

monitoring technology into the 

treatment of hypertension for patients 

served by participating health centers. 

The project will also utilize the 

American Heart Association’s targeted 

media campaigns and existing 

partnerships with community-based 

organizations (CBOs) to help reach 

Black, Latino, and other impacted 

communities with (i) culturally and 

linguistically appropriate messages, (ii) 

access to blood pressure screenings, and 

(iii) connection to health centers to 

encourage proper treatment and 

management of hypertension of 

screened individuals. This initiative 

serves to increase the number of adult 

patients with controlled hypertension 

and reduce the potential risk of COVIDrelated health outcomes. 

AHA aims to conduct an evaluation to 

assess the feasibility of the 

implementation of each of the three 

NHCI strategies. The findings of this 

evaluation will inform the improvement 

and tailoring of AHA’s communication 

approaches about the importance of and 

techniques for improving blood pressure 

control, including the benefits of 

accurately measuring, rapidly acting, 

and having a patient-focused approach 

to blood pressure control. 

Methodology: The evaluation of the 

NHCI project will use a mixed methods 

design, integrating both quantitative and 

qualitative data collection and analyses. 

Three main goals of data collection will 

be to: (1) Track and monitor systems 

change implementation process 

information from Community Health 

Centers (CHCs) on a quarterly basis, (2) 

assess the capacity of NHCI partners to 

implement the NHCI project, their 

needs, the strengths and weaknesses of 

the systems change approach, and the 

feasibility of the implementation of the 

NHCI in their organizations and 

communities, and (3) assess the reach 

and success of NHCI project strategies 

implemented by partners. 

Federal Register / Vol. 86, No. 179 / Monday, September 20, 2021 / Notices 52161 

ANNUALIZED BURDEN HOUR TABLE

Respondents 

(If necessary) 

Number of 

respondents 

Number of 

responses per 

respondents 

Average 

burden per 

response 

Total burden 

hours 

Community and Social Service Occupations (CBO quarterly data entry into 

MERD) .......................................................................................................... 53 4 30/60 106 

Consumers (ETS health lesson learning questionnaires) ............................... 63,600 1 10/60 10,600 

Health care professionals (quarterly data entry in MERD) ............................. 350 4 1.5 2100 

Health care professionals (annual focus group) .............................................. 16 1 1.5 24 

Community and Social Service Occupations (annual focus group) ................ 16 1 1.5 24 

Total .......................................................................................................... 64,035 ........................ ........................ 12,854 

Sherrette A. Funn, 

Paperwork Reduction Act Reports Clearance 

Officer, Office of the Secretary. 

[FR Doc. 2021–20276 Filed 9–17–21; 8:45 am] 

BILLING CODE 4150–29–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Biobehavioral and 

Behavioral Processes Integrated Review 

Group; Human Complex Mental Function 

Study Section. 

Date: October 14–15, 2021 

Time: 10:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Joanna Szczepanik, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institute of 

Health, 6701 Rockledge Drive, Room 1000D 

Bethesda, MD 20892 (301) 827–2242 

szczepaj@csr.nih.gov 

Name of Committee: Biology of 

Development and Aging Integrated Review 

Group; Mechanisms of Cancer 

Therapeutics—1 Study Section. 

Date: October 18–19, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Maria Dolores Arjona 

Mayor, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institute of Health, 6701 Rockledge Drive, 

Room 806D, Bethesda, MD 20892, (301) 827– 

8578, dolores.arjonamayor@nih.gov. 

Name of Committee: Interdisciplinary 

Molecular Sciences and Training Integrated 

Review Group; Cellular and Molecular 

Technologies Study Section. 

Date: October 20–21, 2021. 

Time: 10:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Tatiana V. Cohen, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5213, 

Bethesda, MD 20892, 301–455–2364, 

tatiana.cohen@nih.gov. 

Name of Committee: Biology of 

Development and Aging Integrated Review 

Group; Drug Discovery and Molecular 

Pharmacology Study Section. 

Date: October 21–22, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Jeffrey Smiley, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 6194, 

MSC 7804 Bethesda, MD 20892, 301–594– 

7945 smileyja@csr.nih.gov. 

Name of Committee: Brain Disorders and 

Clinical Neuroscience Integrated Review 

Group; Acute Neural Injury and Epilepsy 

Study Section. 

Date: October 21–22, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892 

(Virtual Meeting). 

Contact Person: Paula Elyse Schauwecker, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 5201, 

Bethesda, MD 20892, 301–760–8207, 

schauweckerpe@csr.nih.gov. 

Name of Committee: Infectious Diseases 

and Immunology B Integrated Review Group; 

Clinical Research and Field Studies of 

Infectious Diseases Study Section. 

Date: October 21–22, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Pauline Cupit, Ph.D., 

Scientific Review Office,r Center for 

Scientific Review National Institute of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892 301–827–3275, cupitcunninghpm@

mail.nih.gov. 

Name of Committee: Healthcare Delivery 

and Methodologies Integrated Review Group; 

Interdisciplinary Clinical Care in Specialty 

Care Settings Study Section. 

Date: October 21–22, 2021. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Abu Saleh Mohammad 

Abdullah, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Bethesda, MD 20892, (301) 827–4043, 

abuabdullah.abdullah@nih.gov. 

Name of Committee: Genes, Genomes, and 

Genetics Integrated Review Group; Genomics 

Computational Biology and Technology 

Study Section. 

Date: October 21–22, 2021. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge, Drive 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Methode Bacanamwo, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 2200, 

Bethesda, MD 20892 301–827–7088, 

methode.bacanamwo@nih.gov. 

Name of Committee: Cardiovascular and 

Respiratory Sciences Integrated Review 

Group; Clinical Integrative Cardiovascular 

and Hematological Sciences Study Section. 

Date: October 21–22, 2021. 

Time: 9:00 a.m. to 6:00 p.m.